Effectiveness of cetuximab as preemptive postsurgical therapy for oral squamous cell carcinoma patients with major risk: a single-center retrospective cohort study.

Invest New Drugs · 2021 · PMC8068704 · PMID 33449240

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

close to significancep = 0.054so close (0.05 < p ≤ 0.1)

In contrast, mortality was significantly decreased by cetuximab treatment in univariate analysis (HR: 0.228, 95% CI: 0.054–0.968, p = 0.045) and was decreased with close to significance in multivariate analysis (HR: 0.233, 95% CI: 0.053–1.028, p = 0.054) (Table 3 ).

also in 2,130 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.